Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Trial Details

NCT ID

NCT07106762

Phase

PHASE2 / PHASE3

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Bladder Cancer

Interventions

• Iza-bren
• Cisplatin
• Gemcitabine
• Carboplatin

Locations (sample)

• Gilbert, Arizona, United States|33.35283,-111.78903
• Fullerton, California, United States|33.87029,-117.92534
• Sacramento, California, United States|38.58157,-121.4944
• Denver, Colorado, United States|39.73915,-104.9847
• Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

• Participants must have histologically confirmed advanced urothelial carcinoma.
• Participants must be eligible to receive platinum-based chemotherapy.
• Participants must be Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another syst…
• Participants treated only in the peri-operative setting must have relapsed within 12 months of the last dose of the treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.